AKT1 and Burkitt lymphoma: In summary, targeting PI3K appears to have biological relevance in BL and in vitro targeting of the PI3K/Akt/mTOR pathway in models of BL exhibits promising pre-clinical activity validating further pursuit of novel therapeutic agents targeting this pathway in BL.